Incyte Reports Positive Phase 3 frontMIND Results for Tafasitamab Plus Lenalidomide Added to R-CHOP in First-Line DLBCL and HGBL
Incyte Corporation (Nasdaq: INCY) has announced positive results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in combination with lenalidomide added to standard R-CHOP chemotherapy as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The investigational regimen, referred to as Tafa-Len-R-CHOP, demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and event-free survival (EFS) compared with R-CHOP alone, marking a potential advance in the frontline treatment of high-risk B-cell lymphomas.
The results were presented as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and were simultaneously published in The Lancet, underscoring the clinical importance of the findings.
Addressing a Longstanding Need in High-Risk DLBCL
DLBCL is the most common aggressive form of non-Hodgkin lymphoma and is typically treated with R-CHOP, a combination chemotherapy regimen that has remained the standard of care for decades. Despite its widespread use, approximately 40% of patients experience disease relapse or progression following first-line therapy, particularly among those with high-risk features.
The Incyte frontMIND study specifically enrolled adults with previously untreated DLBCL or HGBL who had higher-risk disease characteristics, defined by an International Prognostic Index (IPI) score of 3–5. For younger patients (≤60 years), eligibility required an age-adjusted IPI (aaIPI) of 2–3. These criteria identify populations with more aggressive disease biology and poorer expected outcomes.
Tafasitamab is a humanized Fc-modified monoclonal antibody targeting CD19, designed to enhance immune-mediated cytotoxicity against B cells. When combined with lenalidomide, an immunomodulatory agent, and integrated into the R-CHOP backbone, the regimen aims to improve depth and durability of response in newly diagnosed patients.
Primary Endpoint: Significant Improvement in Progression-Free Survival
The trial met its primary endpoint of investigator-assessed progression-free survival, demonstrating that the addition of tafasitamab and lenalidomide to R-CHOP significantly reduced the risk of disease progression or death.
Patients receiving Tafa-Len-R-CHOP experienced a 25% reduction in risk of progression or death compared with those treated with R-CHOP alone, corresponding to a hazard ratio (HR) of 0.75 (P = 0.0194; 95% CI: 0.59–0.96). The median follow-up period was approximately 35 months, providing a robust dataset for assessing durability of response.
The benefit in PFS was also reflected in absolute improvements over time:
- At 2 years, PFS was 71.1% in the Tafa-Len-R-CHOP arm versus 62.9% with R-CHOP alone, an 8.2% absolute improvement.
- At 3 years, PFS was 67.3% versus 60.7%, a 6.6% absolute improvement favoring the investigational regimen.
These findings suggest that the benefit of adding tafasitamab and lenalidomide to standard chemotherapy is sustained over time rather than being limited to early treatment response.
Importantly, subgroup analyses showed that PFS benefits were generally consistent across key prespecified populations, including both major cell-of-origin (COO) molecular subtypes—activated B-cell-like (ABC) and germinal center B-cell-like (GCB)—as well as centrally confirmed disease subgroups.
Secondary Endpoints: Improvements in Event-Free Survival and Trends in Overall Survival
The Incyte frontMIND trial also met its key secondary endpoint of event-free survival (EFS). Patients treated with Tafa-Len-R-CHOP experienced a statistically significant improvement in EFS compared to R-CHOP alone, with a hazard ratio of 0.79 (P = 0.0260; 95% CI: 0.64–0.97).
Although the overall survival (OS) analysis remains immature, interim results showed a positive trend favoring the investigational regimen. The hazard ratio for OS was 0.85 (P = 0.2703; 95% CI: 0.63–1.14), with a median follow-up of approximately 36 months. Final OS results are expected after longer follow-up, as more events mature.
Clinical Interpretation: A Potential Shift in First-Line Treatment
According to investigators, the magnitude of benefit observed in high-risk patient populations is particularly meaningful given the historical lack of progress in improving frontline outcomes for DLBCL.
Dr. Georg Lenz of University Hospital Münster, principal investigator of the study, noted that R-CHOP has remained the backbone of therapy for decades, yet outcomes remain suboptimal for a substantial proportion of patients. He highlighted that adding tafasitamab and lenalidomide improved outcomes across clinically important subgroups, including those with high-risk disease features, where therapeutic advances have been especially limited.
The data suggest that Tafa-Len-R-CHOP could expand first-line treatment options and potentially redefine the standard of care for select patients with aggressive B-cell lymphoma, pending regulatory review.
Safety Profile: Manageable but with Increased Hematologic Toxicity
The safety profile of Tafa-Len-R-CHOP was generally consistent with the known effects of R-CHOP combined with immunotherapy and lenalidomide. Overall, treatment was considered manageable, and most patients were able to continue therapy without interruption of the R-CHOP backbone.
The most common treatment-emergent adverse events (TEAEs) included:
- Neutropenia (70.7%)
- Anemia (46.3%)
- Peripheral neuropathy (40.6%)
Most adverse events were Grade 1 or Grade 2 in severity. However, Grade ≥3 TEAEs occurred more frequently in the investigational arm (86.7%) compared with R-CHOP alone (76.1%).
The most common Grade 3 events in the Tafa-Len-R-CHOP group included anemia (22.8%), thrombocytopenia (13.1%), and neutropenia (12.4%). In the control arm, the most common Grade 3 events were anemia (15.9%), febrile neutropenia (8.7%), and thrombocytopenia (6.7%).
Despite higher rates of hematologic toxicity, treatment discontinuation rates remained comparable between arms (5.2% vs 5.4%), indicating that adverse events were generally manageable with standard supportive care.
Interestingly, although there was a slightly higher incidence of fatal TEAEs in the investigational arm (5.9% vs 3.8%), the total number of deaths overall was lower in the Tafa-Len-R-CHOP group (18.5%) compared with R-CHOP alone (21.7%), consistent with the observed survival trends.
Mechanistic Rationale: Enhancing Immune-Mediated Tumor Cell Killing
Tafasitamab is engineered to enhance antibody-dependent cellular cytotoxicity (ADCC) against CD19-expressing B cells. When combined with lenalidomide, which modulates immune function and enhances NK and T-cell activity, the regimen is designed to amplify anti-tumor immune responses.
Integrating this immune-activating combination into R-CHOP, which delivers cytotoxic chemotherapy, creates a multi-pronged therapeutic approach targeting lymphoma cells through both direct cytotoxic and immune-mediated mechanisms. This strategy is intended to deepen initial responses and reduce the likelihood of relapse.
Regulatory and Clinical Development Implications
Based on the strength of the Incyte frontMIND data, Incyte plans to pursue global regulatory submissions evaluating tafasitamab and lenalidomide in combination with R-CHOP for previously untreated DLBCL and HGBL.
If approved, the regimen could represent a meaningful evolution in frontline therapy for high-risk B-cell lymphomas, a setting where outcomes have remained largely unchanged despite incremental improvements in supportive care and salvage therapies.
The Phase 3 frontMIND trial results represent a significant development in the treatment landscape for newly diagnosed high-risk DLBCL and HGBL. By demonstrating improvements in progression-free and event-free survival, along with encouraging overall survival trends, the addition of tafasitamab and lenalidomide to R-CHOP may offer a new therapeutic option for patients with historically poor prognoses.
While further follow-up is required to confirm overall survival benefits and long-term safety, the findings support continued regulatory advancement and may ultimately contribute to a new first-line standard of care in aggressive B-cell lymphomas.
About Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults worldwide, representing 40% of all cases.1 It is characterized as an aggressive, fast-growing type of lymphoma that can emerge in lymph nodes or extranodal sites such as the gastrointestinal tract, skin and brain.2 Each year, approximately 24,000 people in the U.S. and up to 36,000 people in Europe are diagnosed with DLBCL.3,4 With about 40% of these patients not responding to initial therapy or relapsing thereafter,5,6 there is a high medical need for new, effective therapies, particularly for high-risk patients.
About frontMIND
The frontMIND trial (NCT04824092) is a randomized, double-blind, placebo-controlled, global Phase 3 study in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).
The study enrolled 899 adults (≥18 to ≤80 years) and is evaluating the efficacy and safety of tafasitamab and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared with R-CHOP alone.
The primary endpoint of the study is investigator-assessed progression-free survival (PFS) using the Lugano 2014 criteria. Key secondary endpoints include event-free survival (EFS) by investigator assessment and overall survival (OS).
For more information about the frontMIND trial, please visit https://www.clinicaltrials.gov/study/NCT04824092.
About Tafasitamab (Monjuvi®/Minjuvi®)
Tafasitamab (Monjuvi®/Minjuvi®) is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.
In the U.S., Monjuvi® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Additionally, Monjuvi received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
Monjuvi is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials.
In Europe, Minjuvi® (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency (EMA) in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. In addition, in December 2025, the EMA approved Minjuvi, in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory FL (Grade 1-3a) after at least one line of systemic therapy.
